Gregory Hayes Email and Phone Number
Gregory Hayes work email
- Valid
- Valid
- Valid
- Valid
- Valid
Gregory Hayes personal email
Gregory Hayes phone numbers
Translational scientist focusing on: • Biomarker discovery & clinical assay development • Companion diagnostic (CDx) strategy and commercial partnerships • Global epidemiology / seroprevalence studies • Drug product mechanisms of action (MOAs) & PK/PD evaluation • GMP protein production & drug substance characterizationDetailed experience driving therapeutics and biomarker programs from early pre-clinical discovery through Ph3 clinical development (including CRO and commercial partnerships, assay transfer activities, regulatory filings, KOL collaborations, patient advocacy engagement)
-
Vice President, Translational MedicineKurome Therapeutics, Inc. Jul 2022 - PresentCincinnati, Ohio, Us
-
Senior Director, Head Of Biomarker DevelopmentBridgebio Jul 2020 - May 2022Palo Alto, California, Us -
Director, Translational Sciences (Clinical Diagnostics)Biomarin Pharmaceutical Inc. Jan 2018 - Jul 2020San Rafael, Ca, Us -
Assoc. Director, Translational SciencesBiomarin Pharmaceutical Inc. Dec 2014 - Dec 2017San Rafael, Ca, Us• Head of companion diagnostic strategy (CDx) across indications and programs, including patient selection within clinical studies, assay development and regulatory strategy (centralized LDT vs de-centralized IVD testing, cut-point threshold validations, study risk determinations & IDEs as needed, PMA/510k submissions), both internal and external CRO assay development including commercial Dx partnerships, head of CDx global regulatory affairs (FDA/EMA/PMDA), and commercial launch / life cycle management to ensure diagnostic approval and successful transition of tests to market alongside drugs• Regulatory lead responsible for filing the first CDx (PMA) in any gene therapy indication• Head global seroprevalence and epidemiology studies in rare disease programs - CRO partnering, academic / KOL collaborations, patient advocacy engagement• Biomarker discovery for multiple pre-clinical through post-approval programs covering oncology and orphan disease drug development.• Talzenna® combination therapy biomarker discovery: PDX xenografts and drug resistance modeling, patient selection and monitoring assay R&D, Myriad BRACAnalysis® CDx strategy
-
Sr Scientist - Pre-Clinical DevelopmentIgenica Inc 2012 - Nov 2014MOA & Biomarker Lead• Identification of anti-tumor mechanisms of action (MOA) covering Igenica’s multiple antibody programs (solid and hematological indications; naked antibodies and drug conjugates)• Core team lead for an immuno-oncology & stromal antibody target (in multiple solid and hematological indications)• Biomarker discovery and strategy for both pre-clinical & clinical assay implementation (diagnostic, patient stratification, drug activity and efficacy, safety, PK/PD)• Direct outsourcing of assays for clinical qualification and validation through bioanalytical partners; identification of critical reagents and appropriate assay platform technologies• Design and implementation of IND-enabling toxicology studies (PK & dose escalation in mice/cynomolgus monkey) at external CROs• Instrumental in the successful filing of Igenica’s first IND and detailed coordination with CRO operations/sites regarding bio-analytical strategy
-
Scientist - Sr ScientistMedimmune 2008 - 2012Gaithersburg, Maryland, UsTranslational Biology Group – CQA Team Lead• Biomarker discovery & development of mechanism of action (MOA) assays for both pre-clinical & clinical programs• Program lead for identification, characterization, and qualification of critical quality attributes (CQAs) for novel programs (subunit + adjuvant, VLPs); serving as the link between research biology, drug product development, and clinical development• Evaluation and implementation of innovative technologies for biomarker discovery and analytical characterization of recombinant antigens• Biological & technical leader of a cancer vaccine program heading a multifunctional team into clinical trial evaluation• Identification and generation of program-specific critical reagents and reference standards• Design and qualification of analytics for drug substance & product characterization (including in vitro & in vivo potency assays)• Generation of a cGMP recombinant antigen production system that serves as a core to multiple CMC programs• Company lead for multiple academic collaborations -
Scientist, OncologyKinemed Inc. 2006 - 2008Emeryville, Ca, UsKinetic Biomarker Development• Clinical development of stable isotope labeling and kinetic cancer biomarkers • Principal Investigator of a multi-center Phase II prognostic biomarker trial (NCT00481858)• Extensive analytical assay qualification and transfer experience to outside collaborative laboratories (site monitoring & audits)• Discovery of a non-invasive biomarker for prostate epithelial cell kinetics • Correlation of tumor cell kinetics to genome wide SNPs and gene expression patterns• Development of a kinetic biomarker for breast ductal carcinoma in situ to predict aggressive disease -
Post-Doctoral FellowMayo Clinic Cancer Center 2002 - 2006• Characterization of alternative pre-mRNA splice patterns in epithelial carcinomas • Identification of new therapeutic targets & strategy • Cancer biomarker discovery
-
Post-Doctoral Fellow (Bone Marrow Transplantation)Rush Cancer Institute 2001 - 2002• Engineering of natural killer cells to enhance anti-tumor efficacy with immunotherapy• Investigation of HLA-G expression & splice patterns in CLL and myeloma • Identification of mechanisms underlying tumor cell resistance to NK cells• cGMP production of effector cells for Phase I/II clinical trials -
Graduate StudentTerry Fox Laboratory (Bc Cancer Agency) & Jonsson Comprehensive Cancer Center (Ucla) 1997 - 2001
Gregory Hayes Skills
Gregory Hayes Education Details
-
The University Of British ColumbiaMedicine (Pathology) -
University Of AlbertaGenetics
Frequently Asked Questions about Gregory Hayes
What company does Gregory Hayes work for?
Gregory Hayes works for Kurome Therapeutics, Inc.
What is Gregory Hayes's role at the current company?
Gregory Hayes's current role is Vice President, Translational Medicine Kurome Therapeutics.
What is Gregory Hayes's email address?
Gregory Hayes's email address is gr****@****rin.com
What is Gregory Hayes's direct phone number?
Gregory Hayes's direct phone number is +141538*****
What schools did Gregory Hayes attend?
Gregory Hayes attended The University Of British Columbia, University Of Alberta.
What skills is Gregory Hayes known for?
Gregory Hayes has skills like Molecular Biology, Cell Biology, Biomarker Discovery, Biomarker Development, Gmp Cell Line Development, Tumor Immunology, Clinical Research, Clinical Trials, Kinetics, Cell Culture, Alternative Splicing, Cellular Manufacturing.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial